The global market for obesity therapeutics has undergone a seismic shift, what does that mean for strategic GLP-1 dealmaking?
Obesity is the hottest sector of the biopharma market, driven by the explosive growth of GLP-1 therapies and the associated dealmaking activity. 2024 alone saw over $30 billion in alliances and acquisitions.
In this report, Evaluate’s dealmaking experts report on the drivers of GLP-1 dealmaking and investigate trends, barriers, and the role of China as a source of innovation.
Read the report to explore:
- Deal trends in obesity including deal stage, key drivers and barriers
- Deal volume by modality, targets and RoA
- Changes in the treatment landscape as innovation shifts to combination therapies
- The investment opportunity as venture dollars continue to pour into the GLP-1 market
